AZD3759, also known as Zorifertinib, is a type of EGFR-TKI specially designed to treat brain metastatic NSCLC patients because of its ability to penetrate the BBB, which shows significant affinity for L858R mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.